Array
(
[results] => Array
(
[0] => Array
(
[ArticleID] => 1292902
[Title] => New Biologic Drug Is Targeted Treatment for Ovarian Cancer
[Summary] => Researchers have announced the development of a new biologic drug targeted to treat ovarian cancer. Its design could improve the treatment and survival statistics for some women suffering from this type of malignancy.
[DatePublished] => 2014-02-21 07:00:05
[ColumnID] => 0
[Focus] => 0
[AuthorID] => 1788586
[AuthorName] => Vonda J. Sines
[SectionName] => Health And Family
[SectionUrl] => health-and-family
[URL] => http://img834.imageshack.us/img834/1294/46r7.jpg
)
[1] => Array
(
[ArticleID] => 850063
[Title] => Women urged to start pelvic exams at 40
[Summary] => Women usually experience pelvic discomfort or bloating at different periods of their life. Increased abdominal girth that makes clothes fit tighter around the waist is a common condition that many women ignore, or just attribute to eating too much or aging.
[DatePublished] => 2012-09-18 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Health And Family
[SectionUrl] => health-and-family
[URL] =>
)
[2] => Array
(
[ArticleID] => 743585
[Title] => Roche launches drug for advanced ovarian cancer
[Summary] => Pharmaceutical company Roche recently launched an important milestone making its targeted therapy bevacizumab available for a disease where few treatment advances have been seen in over two decades.
[DatePublished] => 2011-11-03 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
[3] => Array
(
[ArticleID] => 742896
[Title] => First-line treatment for advanced ovarian cancer
[Summary] => Pharmaceutical company Roche recently launched an important milestone making its targeted therapy bevacizumab available for a disease where few treatment advances have been seen in over two decades.
[DatePublished] => 2011-11-01 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Health And Family
[SectionUrl] => health-and-family
[URL] =>
)
[4] => Array
(
[ArticleID] => 731565
[Title] => Treatment for advanced ovarian cancer receives positive opinion
[Summary] => BASEL, Switzerland — Roche has announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the use of bevacizumab in combination with standard chemotherapy (carboplatin and paclitaxel) as a front-line treatment for women with advanced ovarian cancer.
[DatePublished] => 2011-09-29 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
[5] => Array
(
[ArticleID] => 701306
[Title] => Researchers analyze gene changes in ovarian cancer
[Summary] => Researchers analyzing the genetic makeup of ovarian cancer tumors have found a gene mutation that is surprisingly frequent, suggesting it plays a key role in driving the cancer.
[DatePublished] => 2011-07-01 02:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] =>
[SectionUrl] =>
[URL] =>
)
[6] => Array
(
[ArticleID] => 696213
[Title] => Roche drug halves risk of disease worsening in women with recurrent ovarian cancer
[Summary] => Roche recently announced the results from OCEANS, a phase III study evaluating bevacizumab in combination with chemotherapy (gemcitabine and carboplatin) followed by the continued use of bevacizumab alone in women with previously treated (recurrent) platinum-sensitive ovarian cancer.
[DatePublished] => 2011-06-16 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
[7] => Array
(
[ArticleID] => 685871
[Title] => CA 125 plus ultrasound detects early ovarian ca
[Summary] => Large-scale screening for ovarian cancer with a combination of transvaginal ultrasound and cancer antigen 125 is a feasible strategy that can accurately identify early cancers, a large UK trial of almost 203,000 women concluded.
[DatePublished] => 2011-05-15 00:00:00
[ColumnID] => 136231
[Focus] => 0
[AuthorID] => 1805110
[AuthorName] => Charles C. Chante MD
[SectionName] => Opinion
[SectionUrl] => opinion
[URL] =>
)
[8] => Array
(
[ArticleID] => 676897
[Title] => IVF regimen linked to ovarian cancer risk
[Summary] => Ovarian stimulation for in vitro fertilization was linked to an increased risk of ovarian cancer 15 years later in a large cohort study that followed thousands of women in the Netherlands.
[DatePublished] => 2011-04-17 00:00:00
[ColumnID] => 136231
[Focus] => 0
[AuthorID] => 1805110
[AuthorName] => Charles C. Chante MD
[SectionName] => Opinion
[SectionUrl] => opinion
[URL] =>
)
[9] => Array
(
[ArticleID] => 657719
[Title] => Treatment helps women with ovarian cancer live significantly longer
[Summary] => Roche announced this week that OCEANS, a phase III study evaluating bevacizumab in combination with chemotherapy (carboplatin and gemcitabine) followed by continued use of bevacizumab alone until disease progression in women with previously treated (recurrent), platinum-sensitive ovarian cancer, met its primary endpoint.
[DatePublished] => 2011-02-17 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
)
)
